AzTrials
AzTrials

Breast CancerNCT00892515

Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer

A study testing exercise intervention, counseling intervention and gas chromatography in people with Breast Cancer and Healthy, no Evidence of Disease, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

RATIONALE: Exercise may change the risk of developing breast cancer. It is not yet known whether low-intensity exercise or high-intensity exercise is more effective in lowering the risk of breast cancer. Read more about this study

Who is it for?
Ages 18 to 35 years, women onlyHealthy volunteers can take part
What is being tested?
exercise intervention, counseling intervention and gas chromatography
Could I receive a placebo?
No, everyone receives an active treatment
How many people
183 participants
Where
1 siteUnited States
Study dates
Oct 2008to 20 May 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Women only
  • Healthy volunteers accepted
  • Adult

DISEASE CHARACTERISTICS:

  • Healthy women with ≥ 18% lifetime risk for breast cancer as evidenced by the following:
  • Documentation from a genetic counselor of a known familial breast cancer susceptibility mutation
  • Claus model risk of ≥18%
  • Predicted probability of BRCA1/2 mutation > 25% based on the Myriad model
  • Documentation of a known mutation in a family member such that the Mendelian probability of a BRCA1/2 mutation would be >25%
  • History of lobular carcinoma in situ
  • No prior prophylactic mastectomy
  • Leisure-time exercise energy expenditure of ≤ 500 kcal/week over the past 6 months
  • Hormone receptor status not specified

PATIENT CHARACTERISTICS:

  • Premenopausal
  • Menstrual cycles 25-32 days in length
  • Intact ovaries and uterus
  • Gynecologic age (defined as participant's current age minus the age at which she started menstruating) of at least 4 years
  • Body mass index 21-50
  • No history of menstrual difficulties
  • No history of physician-diagnosed gynecological disease (e.g., fibroids, endometriosis, or polycystic ovary syndrome)
  • Not pregnant
  • Not planning to become pregnant during the study period
  • No medical conditions or medications that would prohibit participation in aerobic exercise or would negatively impact the study
  • No history of cancer, except nonmelanoma skin cancers, and in situ cervical cancers
  • No eating disorders (e.g., bulimia or binge-eating disorder)
  • At least one year since prior smoking
  • Not planning to move away from the area during the period of the study
  • No concurrent participation in any weight loss programs

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • At least 3 months since prior hormonal contraception
  • Must use effective non-hormonal contraception unless participant has undergone prior tubal ligation
  • Consumes no more than 7 alcoholic beverages per week

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104-4283

Other trials in United States

About this study

Official title: Women In Steady Exercise Research (WISER) Sister

RATIONALE: Exercise may change the risk of developing breast cancer. It is not yet known whether low-intensity exercise or high-intensity exercise is more effective in lowering the risk of breast cancer.

PURPOSE: This randomized clinical trial is studying how well exercise programs work in healthy young women at increased risk of developing breast cancer.

Read the detailed description

OBJECTIVES:

Primary

  • To conduct a dose response study of low- or high-dose exercise over 5 menstrual cycles, with no concomitant dietary changes producing a caloric deficit, in healthy younger women with ≥ 18% lifetime risk for developing breast cancer.
  • To determine the effects of this exercise regimen on variables known to be associated with breast mitotic activity in these participants.

Secondary

  • To assess changes in other physiologic parameters associated with breast mitotic activity (i.e., urinary progesterone [pregnanediol-glucuronide, PdG] from daily first morning urine samples; follicular phase circulating [serum] levels of estradiol, progesterone, testosterone, and prolactin; follicular phase breast density [fibroglandular tissue volume] from magnetic resonance imaging; estrogen metabolites [estrone, estradiol, estriol, 2-OHE_1, 2-OHE_2, 4-OHE_1, 4-OHE_2, 16-OHE_1 and ratios]; adipokines [i.e., adiponectin and Leptin]; and body composition [i.e., % body fat, lean mass, fat mass, total mass]) in these participants.
  • To assess the extent to which changes in body composition and/or body mass mediate observed changes in these participants.
  • To quantify the relationship between estrogen and progesterone from daily urinary measurements with observed menstrual cycle alterations such as follicular and luteal phase length changes, and ovulatory status in these participants.
  • To compare levels and exercise-induced changes in urinary estrogens, estrogen metabolites, circulating hormones, adipokines, and body size across two groups of women who differ as to breast cancer risk in an exploratory manner.

OUTLINE: Patients are stratified according to body mass index (21-29.9 vs 30-50) and gynecologic age (< 10 vs ≥ 10 years since start of menstruation). Participants are randomized to 1 of 3 intervention arms.

  • Arm I (control): Participants are placed on a waiting list to receive the exercise intervention at completion of the study.
  • Arm II: Participants undergo a low-intensity exercise program comprising 150 minutes of exercise per week for 20 weeks. They are given a treadmill at the beginning of the study and offered ongoing support from a certified exercise professional. Participants may exercise at home on the provided treadmill or at a gym of their choosing. Participants must maintain weekly contact with the exercise professional for the duration of the study, either by phone for brief phone counseling or at a weekly group exercise session at a participating YMCA. The exercise professional visits the participant's home for the first exercise session of each of the first 5 weeks to help individualize the intensity and duration of the exercise session and to instruct participants on the use of the exercise logs and on injury prevention.

Exercise intensity is measured by a Polar Heart Rate monitor worn by the participant to record heart rate response during exercise. Every two weeks, the exercise professional reviews downloadable heart-rate data from the monitor during the home or group exercise session, to objectively measure exercise adherence and provide guidance and emotional support to the participant.

  • Arm III: Participants undergo a high-intensity exercise program that begins with 150 minutes of exercise per week and then gradually builds to 300 minutes per week over 10 weeks. Participants continue to exercise at the higher level until the end of the 20-week intervention period. Participants also undergo exercise and heart rate monitoring and brief phone counseling as in arm II.

Blood and urine samples are obtained from participants periodically before and/or during study to evaluate factors associated with breast mitotic activity and linked to breast cancer risk: urinary conjugates (i.e., E1G and PdG) by enzyme immunoassays; urinary estrogen metabolites by gas chromatography/mass spectrometry; circulating hormones (i.e., estradiol, progesterone, testosterone, and prolactin) by radioimmunoassay; and adipokines (i.e., adiponectin and leptin) by sandwich ELISA. Participants also undergo physical assessments, including periodic measures of body composition by DEXA, follicular phase breast density (fibroglandular tissue volume) by MRI, and height and weight. Aerobic fitness and physical activity levels are also assessed.

Participants complete surveys and questionnaires periodically during study to obtain information on demographics, health history, medication use, eating disorders, dietary intake, and menstrual history.

Being tested
exercise intervention, counseling intervention, gas chromatography, immunoenzyme technique, immunologic technique
Keywords
breast cancer, healthy, no evidence of disease
Medical subject headings
Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • exercise interventionBehavioural

  • counseling interventionOther

  • gas chromatographyOther

  • immunoenzyme techniqueOther

  • immunologic techniqueOther

  • laboratory biomarker analysisOther

  • mass spectrometryOther

  • physiologic testingOther

  • questionnaire administrationOther

  • survey administrationOther

  • dual x-ray absorptometryProcedure or surgery

  • magnetic resonance imagingProcedure or surgery

  • study of high risk factorsProcedure or surgery

Study groups in NCT00892515
Study groupRoleWhat they receive
exerciseExperimentalNot described
Receives: Behavioral: exercise intervention; Other: counseling intervention; Other: gas chromatography; Other: immunoenzyme technique; Other: immunologic technique; Other: laboratory biomarker analysis; Other: mass spectrometry; Other: physiologic testing; Other: questionnaire administration; Other: survey administration; Procedure: dual x-ray absorptometry; Procedure: magnetic resonance imaging; Procedure: study of high risk factors

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in the area under the curve for urinary estrogen (E1G-AUC) adjusted for cycle length

Secondary outcomes (4)
  1. Effects of exercise on variables known to affect or reflect mitogenic activity as related to breast cancer risk

  2. Changes in other physiologic parameters associated with breast mitotic activity

  3. Extent to which changes in body composition and body mass mediate observed changes in E1G-AUC

  4. Relationship between estrogen and progesterone from daily urinary measurements with observed menstrual cycle alterations (i.e., follicular and luteal phase length changes, and ovulatory status)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 May 2009 (estimated)
  2. Study startOct 2008
  3. Primary completionMay 2012
  4. Study completion20 May 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
Single blind
Enrolment
183 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00892515
Sponsor's protocol ID
CDR0000617105
Other IDs
UPCC-807822, UPCC-09108
Status last verified
Apr 2020
First submitted
1 May 2009
Last updated
16 Apr 2020
Results posted
No
Data monitoring committee
Yes

Publications

  • Boyer AL, Arikawa AY, Schmitz KH, Sturgeon KM. Association of Inflammatory Diets with Inflammatory Biomarkers in Women at High Genetic Risk for Breast Cancer. Nutr Cancer. 2022;74(3):816-819. doi: 10.1080/01635581.2021.1986554. Epub 2021 Oct 6.

    PubMed 34615429

Questions about this trial

What is this clinical trial studying?

A study testing exercise intervention, counseling intervention and gas chromatography in people with Breast Cancer and Healthy, no Evidence of Disease, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in the area under the curve for urinary estrogen (E1G-AUC) adjusted for cycle length. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00892515, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in